August 28, 2026

#lipidomics — Friday, August 28, 2026 (2 items)

hot top new

0		ℹ	Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. (linkinghub.elsevier.com)	Sarraju A … Nissen SE The Lancet 2026-08-28	#clinical trial #rnai #therapeutics #cardiovascular #lipidomics
0		ℹ	FASN-mediated de novo lipogenesis promotes ceramide accumulation and myocardial damage in arrhythmogenic cardiomyopathy. (linkinghub.elsevier.com)	Liu Z … Hu S iScience 2026-08-28	#cardiomyopathy #lipogenesis #lipotoxicity #lipidomics #desmosomal